A Positive, Growth-Based PAM Screen Reveals Non-Canonical Motifs Recognized By the S. Pyogenes Cas9 | AIChE

A Positive, Growth-Based PAM Screen Reveals Non-Canonical Motifs Recognized By the S. Pyogenes Cas9

Authors 

Collias, D. - Presenter, North Carolina State University
Leenay, R. T., North Carolina State University
Slotkowski, R. A., North Carolina State University
Collins, S., North Carolina State University
McGirr, B., North Carolina State University
Jacobsen, T., North Carolina State University
Beisel, C., Helmholtz Institute for RNA-based Infection Research
CRISPR technologies have overwhelmingly relied on the ubiquitous and extensively studied Cas9 from Streptococcus pyogenes (SpCas9). One well-defined feature of SpCas9 is its recognition of the canonical NGG and less-preferred NAG and NGA protospacer-adjacent motifs (PAMs) as the complete set used for target selection and off-target predictions. Here, we report that SpCas9 recognizes additional motifs at levels similar to that of the less-preferred PAMs. These motifs were identified using a positive, growth-based screen in E. coli that surprisingly enriched N(A/C/T)GG sequences over the consensus NGG. The enriched N(A/C/T)GG motif effectively represents an extra N between the target and consensus NGG. DNA binding and cleavage assays in bacteria validated the screen’s enriched sequences while indel formation and subsequent GFP disruption validated the N(C/T)GG motif in mammalian cells. Within these experiments, we found that the first two PAM nucleotides contributed to the overall targeting activity. We also discovered that high-fidelity SpCas9’s recognized the N(C/T)GG motif, while the editing location for SpCas9-derived base editors could be shifted by selecting (C/T)GG or N(C/T)GG PAMs. Finally, we found that these motifs were present but overlooked in high-throughput spacer acquisition and off-target assays. SpCas9 therefore exhibits greater targeting flexibility than previously recognized, with implications for precise editing, off-target predictions, and CRISPR-based immunity.